Showing results (71-80 of 105) with videos related to
Sort By:
Pageof 11
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|September 23, 2023
Safety and effectiveness of tofacitinib in ulcerative colitis: Data from TOFA-UC, a SN-IBD studyFabio Salvatore Macaluso, Elvira D'Antonio, Walter Fries, et al.Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|December 20, 2021
Vedolizumab may be an effective option for the treatment of postoperative recurrence of Crohn's diseaseFabio Salvatore Macaluso, Maria Cappello, Federica Crispino, et al.Virchows Archiv : an International Journal of Pathology|February 4, 2014
The histopathological approach to inflammatory bowel disease: a practice guideCord Langner, Fernando Magro, Ann Driessen, et al.JGH Open : an Open Access Journal of Gastroenterology and Hepatology|March 18, 2021
Ustekinumab in Crohn's disease: Real-world outcomes from the Sicilian network for inflammatory bowel diseasesAnna Viola, Marco Muscianisi, Fabio S Macaluso, et al.Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|July 16, 2018
A real life comparison of the effectiveness of adalimumab and golimumab in moderate-to-severe ulcerative colitis, supported by propensity score analysisSara Renna, Filippo Mocciaro, Marco Ventimiglia, et al.Journal of Gastroenterology and Hepatology|May 20, 2020
A propensity score weighted comparison of vedolizumab and adalimumab in Crohn's diseaseFabio Salvatore Macaluso, Marco Ventimiglia, Walter Fries, et al.Journal of Crohn'S & Colitis|October 13, 2025
Switching to subcutaneous administration may offer more profound remission compared to intensified intravenous therapy in patients with inflammatory bowel disease and partial response following induction with intravenous vedolizumab: the PRIVEDO studyFabio Salvatore Macaluso, Walter Fries, Anna Viola, et al.Inflammatory Bowel Diseases|February 22, 2020
The SPOSIB SB2 Sicilian Cohort: Safety and Effectiveness of Infliximab Biosimilar SB2 in Inflammatory Bowel Diseases, Including Multiple SwitchesFabio Salvatore Macaluso, Walter Fries, Anna Viola, et al.Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|August 27, 2025
Comparative effectiveness and safety of tofacitinib and filgotinib in patients with ulcerative colitis: A propensity score-weighted cohort studyFabio Salvatore Macaluso, Walter Fries, Anna Viola, et al.Expert Opinion on Biological Therapy|September 28, 2020
Effectiveness of Ustekinumab on Crohn's Disease Associated Spondyloarthropathy: Real-World Data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD)Fabio Salvatore Macaluso, Walter Fries, Anna Viola, et al.Pageof 11